Novo Nordisk, Eli Lilly & Co. and Sanofi dominate the market for insulin products worldwide, while the much-smaller Biocon is a key player in the copycat segment. The global insulin-pen market is ...

Pharmaceutical giant Novo Nordisk will lower the cost of several of its insulin products by up to 75% next year. Effective January 2024, the list price for insulin brands, including NovoLog and ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin pens to $1 per device in low- and middle-income countries (LMICs).

Analog insulin will still be available in the pen format under Novo's plan. Back in June, The New York Times reported that South Africa’s public health system had run out of human insulin pens ...

Novo launched the NovoPen - the first insulin pen device in 1985. Lars Rebien Sorensen becomes CEO after serving as the head of Novo's healthcare business. The company's enzymes business was spun ...

followed by discontinuation of the Levemir injection pen in April and of Levemir vials by the end of 2024. Sign up here. Novo has another long-acting insulin, Tresiba, on the market. "Novo Nordisk ...

Novo Nordisk said the price of its fast-acting insulins, NovoLog and NovoLog Mix 70/30, will be reduced by 75% to $72.34 per vial and $139.71 for a pen. Its long-acting insulin, Levemir ...

Novo Nordisk plans to slash the U.S. list prices for several of its insulin drugs by as much as 75%, the company said on Tuesday. The move follows Eli Lilly's announcement earlier this month that ...

In the U.S., Novo Nordisk’s recent decision ... They’re filled in pen devices that are similar to the pens that many insulin products come in. As demand for GLP-1s continues to climb, patients ...

Advance Market Analytics published a new research publication on “Global Diabetes Insulin Pen Market Insights ... States), Medtronic (Ireland), Novo Nordisk (Denmark), Sanofi (France), Becton ...